Research Article
Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection
Table 1
Demographics and clinicopathologic characteristics of chronic hepatitis B patients enrolled in the study.
| | Training set () | Validation set () | | Variable | No. of patients | % | No. of patients | % | |
| Gender | | | | | 0.080 | Male | 668 | 72.77 | 370 | 77.08 | | Age (years) | 34.91 (28.96, 42.75) | | 35.99 (29.34, 42.68) | | 0.243 | <40 | 610 | 66.45 | 307 | 63.96 | | ≥40; <60 | 274 | 29.85 | 156 | 32.50 | | ≥60 | 34 | 3.70 | 17 | 3.54 | | BMI (kg/m2) | 21.80 (19.82, 24.35) | | 22.04 (19.65, 24.69) | | 0.448 | <18.5 | 120 | 13.07 | 63 | 13.13 | | ≥18.5; <25 | 606 | 66.01 | 305 | 63.54 | | ≥25; <30 | 180 | 19.61 | 108 | 22.50 | | ≥30 | 12 | 1.31 | 4 | 0.83 | | History of alcohol intake | 98 | 10.68 | 60 | 12.50 | 0.306 | Family history of HBV | 556 | 60.57 | 294 | 61.25 | 0.804 | Family history of HCC | 96 | 10.46 | 54 | 11.25 | 0.649 | HCC | | | | | 0.186 | HCC on inclusion | 11 | 1.20 | 8 | 1.67 | | New-onset HCC | 3 | 0.33 | 5 | 1.04 | | AST (U/l) | 36 (26, 59) | | 35 (26, 66) | | 0.726 | ≥15; <40 | 519 | 56.54 | 274 | 57.08 | | ≥40 | 390 | 42.48 | 204 | 42.50 | | ALT (U/l) | 38 (24, 76) | | 38 (25, 72) | | 0.917 | ≥3; <35 | 420 | 45.75 | 222 | 46.25 | 0.859 | ≥35 | 498 | 54.25 | 258 | 53.75 | 0.859 | Albumin (g/l) | 45.50 (43.39, 47.60) | | 45.30 (42.90, 47.48) | | 0.239 | <36 | 35 | 3.81 | 13 | 2.71 | 0.282 | Total bilirubin (μmol/l) | 13.84 (10.89, 18.70) | | 14.24 (10.33, 18.70) | | 0.933 | >23.6 | 110 | 11.98 | 65 | 13.54 | 0.403 | HBV DNA log10 (IU/ml) | 4.750 (0, 6.945) | | 4.197 (0, 6.679) | | 0.118 | <2 | 233 | 25.38 | 127 | 26.46 | | ≥2; <4 | 163 | 17.76 | 105 | 21.88 | | ≥4; <7 | 300 | 32.68 | 148 | 30.83 | | >7 | 222 | 24.18 | 100 | 20.83 | | qHBsAg log10 (IU/ml) | 3.673 (3.200, 3.862) | | 3.738 (3.218, 3.888) | | 0.235 | ≤1 | 18 | 1.96 | 11 | 2.29 | | >1; ≤2 | 30 | 3.27 | 16 | 3.33 | | >2; ≤3 | 123 | 13.40 | 57 | 11.88 | | >3 | 747 | 81.37 | 396 | 82.50 | | HBeAg status | | | | | 0.504 | Positive | 482 | 52.51 | 243 | 50.63 | | Negative | 436 | 47.49 | 237 | 49.38 | | HBsAg loss | 35 | 3.81 | 22 | 4.58 | 0.489 | Antiviral treatment | 666 | 72.55 | 346 | 72.08 | 0.853 | Follow-up time (months) | 75 (52, 90) | | 75 (51, 89) | | 0.905 |
|
|
Abbreviations: CHB: chronic hepatitis B; BMI: body mass index; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HBV DNA: hepatitis B viral deoxyribonucleic acid load at baseline; qHBsAg: quantitative hepatitis B virus surface antigen; HBeAg: hepatitis B virus e-antigen.
|